Showing results (2241-2250 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|August 13, 2019
Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitorsSadal Refae, Jocelyn Gal, Nathalie Ebran, et al.
Investigational New Drugs|August 4, 2019
Ibrutinib as a potential therapeutic option for HER2 overexpressing breast cancer - the role of STAT3 and p21Chandra Bose Prabaharan, Allan Boyao Yang, Divya Chidambaram, et al.
Investigational New Drugs|May 20, 2015
In vitro and in vivo toxicity of 5-FdU-alendronate, a novel cytotoxic bone-seeking duplex drug against bone metastasisSarah Schott, Sonia Vallet, Robert J Tower, et al.
Investigational New Drugs|May 21, 2015
Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liverRabih Said, Razelle Kurzrock, Aung Naing, et al.
Investigational New Drugs|April 30, 2015
AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - results of two parallel first-in-human phase I studiesA Omlin, R J Jones, R van der Noll, et al.
Investigational New Drugs|May 8, 2015
The effect of paclitaxel and nab-paclitaxel in combination with anti-angiogenic therapy in breast cancer cell linesFederica Tonissi, Laura Lattanzio, Marco C Merlano, et al.
Investigational New Drugs|April 22, 2015
Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumorsJennifer R Diamond, Benjamin Wu, Neeraj Agarwal, et al.
Investigational New Drugs|January 1, 1997
Discovery of cryptophycin-1 and BCN-183577: examples of strategies and problems in the detection of antitumor activity in miceT H Corbett, F A Valeriote, L Demchik, et al.
Investigational New Drugs|January 1, 1997
Early evaluation of liposomal daunorubicin (DaunoXome, Nexstar) in the treatment of relapsed and refractory lymphomaD S Richardson, S M Kelsey, S A Johnson, et al.
Investigational New Drugs|May 9, 2015
Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium studyKatrina S Pedersen, George P Kim, Nathan R Foster, et al.
Pageof 372